Stay updated on RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma
Sign up to get notified when there's something new on the RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma page.

Latest updates to the RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma page
- Check7 days agoChange DetectedThe metastatic melanoma study record is now available, describing a Phase 2 trial of ipilimumab and nivolumab with or without hypofractionated radiotherapy. It includes participant eligibility, study locations, treatment plans, outcome measures, and record dates.SummaryDifference49%

- Check14 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedA notice was added explaining that NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check28 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s site revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, blocking access to the clinical trial information. The error page shows a minimal header and a standard 403 message indicating restricted access.SummaryDifference18%

Stay in the know with updates to RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma
Enter your email address, and we'll notify you when there's something new on the RadVax Clinical Trial: Immunotherapy and Radiation in Melanoma page.